Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistSunstar Guangzhou Ltd., a pharmaceutical manufacturer, received an FDA Warning Letter on January 22, 2020, regarding drug products under their manufacturing operations. Based on the limited metadata available, the specific nature of the violations cannot be determined, as the subject line and detailed findings are not provided in this summary. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the available information. A review of the complete Warning Letter would be necessary to identify the actual compliance issues cited.